These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 8277209)
61. The promise of immuno-PET in radioimmunotherapy. Verel I; Visser GW; van Dongen GA J Nucl Med; 2005 Jan; 46 Suppl 1():164S-71S. PubMed ID: 15653665 [TBL] [Abstract][Full Text] [Related]
62. Radiation Safety and Accidental Radiation Exposures in Nuclear Medicine. Marengo M; Martin CJ; Rubow S; Sera T; Amador Z; Torres L Semin Nucl Med; 2022 Mar; 52(2):94-113. PubMed ID: 34916044 [TBL] [Abstract][Full Text] [Related]
63. A feasibility study of the therapeutic application of a mixture of De Nardo L; Pupillo G; Mou L; Esposito J; Rosato A; Meléndez-Alafort L Med Phys; 2022 Apr; 49(4):2709-2724. PubMed ID: 35134261 [TBL] [Abstract][Full Text] [Related]
64. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. Sharkey RM; Goldenberg DM J Nucl Med; 2005 Jan; 46 Suppl 1():115S-27S. PubMed ID: 15653660 [TBL] [Abstract][Full Text] [Related]
65. Fundamentals of radioimmunotherapy. Eary JF Int J Rad Appl Instrum B; 1991; 18(1):105-8. PubMed ID: 2010294 [TBL] [Abstract][Full Text] [Related]
67. Radiation safety considerations for the use of ²²³RaCl₂ DE in men with castration-resistant prostate cancer. Dauer LT; Williamson MJ; Humm J; O'Donoghue J; Ghani R; Awadallah R; Carrasquillo J; Pandit-Taskar N; Aksnes AK; Biggin C; Reinton V; Morris M; St Germain J Health Phys; 2014 Apr; 106(4):494-504. PubMed ID: 24562070 [TBL] [Abstract][Full Text] [Related]
69. Radionuclide therapy of cancer with radiolabeled antibodies. Boerman OC; Koppe MJ; Postema EJ; Corstens FH; Oyen WJ Anticancer Agents Med Chem; 2007 May; 7(3):335-43. PubMed ID: 17504159 [TBL] [Abstract][Full Text] [Related]
70. Proceedings of the 1st International Symposium on Radionuclide Therapy and Radiopharmaceutical Dosimetry. September 4-8, 2004, Helsinki, Finland. Cancer Biother Radiopharm; 2005 Feb; 20(1):41-118. PubMed ID: 15778578 [No Abstract] [Full Text] [Related]
72. Cellular Response to Exponentially Increasing and Decreasing Dose Rates: Implications for Treatment Planning in Targeted Radionuclide Therapy. Solanki JH; Tritt T; Pasternack JB; Kim JJ; Leung CN; Domogauer JD; Colangelo NW; Narra VR; Howell RW Radiat Res; 2017 Aug; 188(2):221-234. PubMed ID: 28541775 [TBL] [Abstract][Full Text] [Related]
73. Radionuclide therapy: current status and prospects for internal dosimetry in individualized therapeutic planning. Sapienza MT; Willegaignon J Clinics (Sao Paulo); 2019; 74():e835. PubMed ID: 31365617 [TBL] [Abstract][Full Text] [Related]
74. Renal toxicity after radionuclide therapy. Lambert B; Cybulla M; Weiner SM; Van De Wiele C; Ham H; Dierckx RA; Otte A Radiat Res; 2004 May; 161(5):607-11. PubMed ID: 15161361 [TBL] [Abstract][Full Text] [Related]
75. A theoretical radiobiological assessment of the influence of radionuclide half-life on tumor response in targeted radiotherapy when a constant kidney toxicity is maintained. Abou-Jaoudé W; Dale R Cancer Biother Radiopharm; 2004 Jun; 19(3):308-21. PubMed ID: 15285877 [TBL] [Abstract][Full Text] [Related]
76. Summary and perspectives on kidney dose-response to radionuclide therapy. Wessels B Cancer Biother Radiopharm; 2004 Jun; 19(3):388-90. PubMed ID: 15285887 [No Abstract] [Full Text] [Related]
77. Additional hepatic Braat AJAT; Kwekkeboom DJ; Kam BLR; Teunissen JJM; de Herder WW; Dreijerink KMA; van Rooij R; Krijger GC; de Jong HWAM; van den Bosch MAAJ; Lam MGEH BMC Gastroenterol; 2018 Jun; 18(1):84. PubMed ID: 29902988 [TBL] [Abstract][Full Text] [Related]
78. Assessments for high dose radionuclide therapy treatment planning. Fisher DR Radiat Prot Dosimetry; 2003; 105(1-4):581-6. PubMed ID: 14527031 [TBL] [Abstract][Full Text] [Related]
79. Systemic targeted radionuclide therapy: potential new areas. Wong JY Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S74-82. PubMed ID: 16979445 [TBL] [Abstract][Full Text] [Related]